What's Next For The CGT Industry? Mid-Year Check-In From The Leadership Team

As 2025 reaches its halfway point, the cell and gene therapy (CGT) industry finds itself at a critical juncture. Scientific breakthroughs continue to move at an impressive pace, yet the infrastructure and systems needed to support commercialization are still lagging behind. To better understand the evolving dynamics, industry leaders across product development, operations, commercial strategy, and client engagement have shared their cross-functional perspectives on where the field is headed.

The outlook reveals a rapidly changing environment shaped by constrained funding, heightened regulatory complexity, and global geopolitical shifts. To stay competitive, CGT developers are rethinking their approaches, prioritizing execution, forming more strategic partnerships, and leveraging operational integration. The shift from transactional vendor relationships to fully integrated solutions is accelerating, especially as early-stage programs push toward commercialization and scale.

Discover how leading cell and gene therapy stakeholders are adapting to industry-wide shifts, and how your team can turn today's challenges into tomorrow's competitive advantage.